Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jul 2018
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms onset9
- Sponsors Novo Nordisk
- 10 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2017 Planned End Date changed from 28 Jan 2019 to 29 Jan 2019.
- 20 Sep 2017 Status changed from not yet recruiting to recruiting.